Mast Therapeutics Inc (NASDAQ:MSTX) had its price objective lifted by S&P Equity Research from $0.08 to $0.09 in a research report issued on Friday. S&P Equity Research’s price objective points to a potential upside of 4.41% from the stock’s current price.

Several other research analysts have also weighed in on MSTX. Zacks Investment Research lowered Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Mast Therapeutics in a report on Tuesday, July 12th. Roth Capital reissued a “buy” rating and set a $2.00 target price on shares of Mast Therapeutics in a report on Friday, July 15th. Canaccord Genuity reissued a “buy” rating and set a $3.00 target price on shares of Mast Therapeutics in a report on Thursday, July 28th. Finally, Laidlaw lowered Mast Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, September 21st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Mast Therapeutics presently has an average rating of “Hold” and a consensus target price of $2.07.

Analyst Recommendations for Mast Therapeutics (NASDAQ:MSTX)

Shares of Mast Therapeutics (NASDAQ:MSTX) traded down 7.19% during midday trading on Friday, reaching $0.08. 8,570,435 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $0.33 and a 200-day moving average of $0.36. Mast Therapeutics has a 1-year low of $0.08 and a 1-year high of $0.71. The company’s market capitalization is $16.95 million.

Mast Therapeutics (NASDAQ:MSTX) last released its earnings results on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities analysts expect that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. boosted its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent filing with the SEC.

Mast Therapeutics Company Profile

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

5 Day Chart for NASDAQ:MSTX

Receive News & Stock Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related stocks with our FREE daily email newsletter.